Patents by Inventor Anja Smith
Anja Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230272394Abstract: Isolation or in vitro assembly of the Cas9-crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system and use for cleavage of DNA bearing a nucleotide sequence complementary to the crRNA and a proto-spacer adjacent motif. Methods for site-specific modification of a target DNA molecule in vitro or in vivo using an RNA-guided DNA endonuclease comprising RNA sequences and at least one of an RuvC active site motif and an HNH active site motif; for conversion of Cas9 polypeptide into a nickase cleaving one strand of double-stranded DNA by inactivating one of the active sites (RuvC or HNH) in the polypeptide by at least one point mutation; for assembly of active polypeptide-polyribonucleotides complex in vivo or in vitro; and for re-programming a Cas9-crRNA complex specificity in vitro and using a cassette containing a single repeat-spacer-repeat unit.Type: ApplicationFiled: December 13, 2022Publication date: August 31, 2023Applicant: VILNIUS UNIVERSITYInventors: Virginijus SIKSNYS, Giedrius GASIUNAS, Tautvydas KARVELIS, Arvydas LUBYS, Lolita ZALIAUSKIENE, Monika GASIUNIENE, Anja SMITH
-
Patent number: 11555187Abstract: Isolation or in vitro assembly of the Cas9-crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system and use for cleavage of DNA bearing a nucleotide sequence complementary to the crRNA and a proto-spacer adjacent motif. Methods for site-specific modification of a target DNA molecule in vitro or in vivo using an RNA-guided DNA endonuclease comprising RNA sequences and at least one of an RuvC active site motif and an HNH active site motif; for conversion of Cas9 polypeptide into a nickase cleaving one strand of double-stranded DNA by inactivating one of the active sites (RuvC or HNH) in the polypeptide by at least one point mutation; for assembly of active polypeptide-polyribonucleotides complex in vivo or in vitro; and for re-programming a Cas9-crRNA complex specificity in vitro and using a cassette containing a single repeat-spacer-repeat unit.Type: GrantFiled: December 7, 2017Date of Patent: January 17, 2023Assignee: Vilnius UniversityInventors: Virginijus {hacek over (S)}ik{hacek over (s)}nys, Giedrius Gasiunas, Tautvydas Karvelis, Arvydas Lubys, Lolita Zaliauskiene, Monika Gasiuniene, Anja Smith
-
Publication number: 20180187195Abstract: Isolation or in vitro assembly of the Cas9-crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system and use for cleavage of DNA bearing a nucleotide sequence complementary to the crRNA and a proto-spacer adjacent motif. Methods for site-specific modification of a target DNA molecule in vitro or in vivo using an RNA-guided DNA endonuclease comprising RNA sequences and at least one of an RuvC active site motif and an HNH active site motif; for conversion of Cas9 polypeptide into a nickase cleaving one strand of double-stranded DNA by inactivating one of the active sites (RuvC or HNH) in the polypeptide by at least one point mutation; for assembly of active polypeptide-polyribonucleotides complex in vivo or in vitro; and for re-programming a Cas9-crRNA complex specificity in vitro and using a cassette containing a single repeat-spacer-repeat unit.Type: ApplicationFiled: December 7, 2017Publication date: July 5, 2018Applicant: VILNIUS UNIVERSITYInventors: Virginijus SIKSNYS, Giedrius GASIUNAS, Tautvydas KARVELIS, Arvydas LUBYS, Lolita ZALIAUSKIENE, Monika GLEMZAITE, Anja SMITH
-
Patent number: 9150862Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.Type: GrantFiled: August 27, 2013Date of Patent: October 6, 2015Assignees: Thermo Fisher Scientific Inc., Arrowhead Research CorporationInventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
-
Publication number: 20150050699Abstract: Isolation or in vitro assembly of the Cas9-crRNA complex of the Streptococcus thermophilus CRISPR3/Cas system and use for cleavage of DNA bearing a nucleotide sequence complementary to the crRNA and a proto-spacer adjacent motif. Methods for site-specific modification of a target DNA molecule in vitro or in vivo using an RNA-guided DNA endonuclease comprising RNA sequences and at least one of an RuvC active site motif and an HNH active site motif; for conversion of Cas9 polypeptide into a nickase cleaving one strand of double-stranded DNA by inactivating one of the active sites (RuvC or HNH) in the polypeptide by at least one point mutation; for assembly of active polypeptide-polyribonucleotides complex in vivo or in vitro; and for re-programming a Cas9-crRNA complex specificity in vitro and using a cassette containing a single repeat-spacer-repeat unit.Type: ApplicationFiled: March 20, 2013Publication date: February 19, 2015Inventors: Virginijus Siksnys, Giedrius Gasiunas, Tautvydad Karvelis, Arvydas Lubys, Lolita Zaliauskiene, Monika Glemzaite, Anja Smith
-
Publication number: 20140066595Abstract: Cell-free extracts, methods for producing these extracts, methods for using these extracts, compositions that facilitate production of these extracts and kits that contain these extracts are provided. By increasing or decreasing certain gene products through, for example, the use of siRNA or mimics, one can develop mammalian cell-free extracts that have desired levels of efficiency.Type: ApplicationFiled: August 26, 2013Publication date: March 6, 2014Applicant: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.Inventors: Emily Anderson, Peter Bell, Penny Jensen, Jon Karpilow, Anja Smith, Krishna Vattem, Brian Webb, Devin Leake, Alex Medford, Elena Maksimova, Craig Smith
-
Publication number: 20140031414Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.Type: ApplicationFiled: August 27, 2013Publication date: January 30, 2014Applicants: ALCON RESEARCH, LTD., THERMO FISHER SCIENTIFIC BIOSCIENCES INC.Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
-
Patent number: 8546349Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.Type: GrantFiled: July 26, 2011Date of Patent: October 1, 2013Assignees: Thermo Fisher Scientific Biosciences Inc., Alcon Research, Ltd.Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
-
Patent number: 8367318Abstract: The disclosure provides methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for a phenotype(s) of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool which comprises at least one miRNA inhibitor specific for each miRNA in the miRNA cluster. MiRNA inhibitors are described that induce apoptosis in breast cancer cells and hence are useful in the treatment of breast cancer. The disclosure also provides pharmaceutical compositions which are useful for the treatment of breast cancer; methods for inducing the nuclear translocation of NF-?B in a breast cancer cell; methods for inducing the nuclear translocation of c-Jun in a breast cancer cell; method for inhibiting the nuclear translocation of NF-?B in a breast cancer cell; and methods for providing prognostic medical information relating to breast cancer progression.Type: GrantFiled: July 21, 2008Date of Patent: February 5, 2013Assignee: Dharmacon, Inc.Inventors: Anja Smith, Scott Baskerville, Devin Leake, Annaleen Vermeulen, Barbara Robertson, Anastasia Khvorova
-
Publication number: 20120029051Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Applicants: ALCON RESEARCH, LTD., DHARMACON, INC.Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
-
Publication number: 20100273856Abstract: The disclosure provides methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for a phenotype(s) of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool which comprises at least one miRNA inhibitor specific for each miRNA in the miRNA cluster. MiRNA inhibitors are described that induce apoptosis in breast cancer cells and hence are useful in the treatment of breast cancer. The disclosure also provides pharmaceutical compositions which are useful for the treatment of breast cancer; methods for inducing the nuclear translocation of NF-?B in a breast cancer cell; methods for inducing the nuclear translocation of c-Jun in a breast cancer cell; method for inhibiting the nuclear translocation of NF-?B in a breast cancer cell; and methods for providing prognostic medical information relating to breast cancer progression.Type: ApplicationFiled: July 21, 2008Publication date: October 28, 2010Applicant: DHARMACON INC.Inventors: Anja Smith, Scott Baskerville, Devin Leake, Annaleen Vermeulen, Barbara Robertson, Anastasia Khvorova